Analysis of the expression of microRNAs in myeloid leukemia, its use as a biomarker of the pathology
DOI:
https://doi.org/10.33448/rsd-v11i14.36538Keywords:
Leukemia; MicroRNA; Biomarker.Abstract
Leukemia has as its main characteristic the accumulation of leukocytes in the bone marrow and blood, with the classification of the place where it will affect and also the speed of progress of the disease. In terms of the progressive speed of this cancer, it stands out chronic and acute, more common in adults and with a delayed symptomatic manifestation and another more common in children and has about 80% of cure. The diagnosis is made through the signs and symptoms present by the patient and together with the blood count. Studies show that the use of miRNAS in the diagnosis of leukemia has become very promising, mainly because it is a painless, less invasive and safe technique, and can also be used to monitor the status of this neoplasm. As a statism, a study showed the use of these RNA molecules that are used to delay cellular apoptosis, consequently prolonging the quality of life of patients with leukemia. In view of these studies, a survey was carried out between August and October 2022, through a descriptive review and survey in the VHL and Pubmed databases, with the purpose of analyzing the profile of miRNAs present in AML and CML, allowing the distinction in the subtypes and degrees, as its association with the diagnosis, prognosis and therapeutic efficacy
References
Boechat, N., Bastos, M, M., Azevedo, L, D., & Oliveira, A. P. (2017). Sínteses e propriedades de fármacos inibidores da tirosina quinase BCR-ABL, utilizados no tratamento da Leucemia Mieloide Crônica. QUÍMICA NOVA (ONLINE), Vol. XY, 01-19.
Barbosa, M. G. A., & de Melo, A. T. (2020). Análise do perfil de miRNAs de leucemias linfocíticas. Brazilian Journal of Development, 6(12), 102464-102472.
Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., & Marcucci, G. (2010). Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences, 107(16), 7473-7478.
Bratz, B. S. G., Gatzke, M., & Frizzo, M. N. (2016). Aspectos Moleculares na Leucemia Linfoide Aguda: Uma Revisão. Newslab, 135 (2016), 1-15.
Butrym, A., Rybka, J., Baczyńska, D., Tukiendorf, A., Kuliczkowski, K., & Mazur, G. (2015). Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. Journal of Experimental & Clinical Cancer Research, 34(1), 1-5. for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. American journal of hematology, 86(2), 237.
Yin, X., Huang, S., Xu, A., Fan, F., Chen, L., Sun, C., & Hu, Y. (2020). Identification of distinctive long noncoding RNA competitive interactions and a six‐methylated‐gene prognostic signature in acute myeloid leukemia with− 5/del (5q) or− 7/del (7q). Journal of Cellular Biochemistry, 121(2), 1563-1574.
Yurt, Y., Ayyıldız, O., Nursal, A. F., & İsi, H. (2020). MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia.
Zhao, J., Lu, Q., Zhu, J., Fu, J., & Chen, Y. X. (2014). Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagnostic pathology, 9(1), 1-6.
Zhi, Y., Xie, X., Wang, R., Wang, B., Gu, W., Ling, Y., & Liu, Y. (2015). Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. International journal of hematology, 102(3), 296-303.
Zhi, Y., Xie, X., Wang, R., Wang, B., Gu, W., Ling, Y., & Liu, Y. (2015). Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. International journal of hematology, 102(3), 296-303.
Zhou, J. D., Zhang, L. C., Zhang, T. J., Gu, Y., Wu, D. H., Zhang, W., & Qian, J. (2018). Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia. Journal of translational medicine, 16(1), 1-10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Émerson Felipe Araújo Barros; Thamyres Fernanda Moura Pedrosa Souza; Michael Gabriel Agustinho Barbosa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
